Form 4: Bausch + Lomb Director Brett Icahn Receives Annual Equity Grant

Bausch + Lomb Corporation's Director, Brett Icahn, was granted 20,338 common shares through an annual restricted share unit award, aligning his interests with shareholders.

Summary

• Bausch + Lomb Corporation Director, Brett Icahn, reported an acquisition of 20,338 common shares.
• The transaction occurred on May 27, 2025.
• These shares were acquired as an annual grant of restricted share units (RSUs) under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• The RSUs were granted at a price of $0, indicating they are compensation.
• Following this transaction, Brett Icahn beneficially owns 61,147 common shares.
• The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders but does not indicate significant new operational or financial developments.

Positives

• The grant of 20,338 restricted share units to Director Brett Icahn aligns his financial interests directly with those of the company's shareholders.
• This is a standard practice for non-employee director compensation, indicating adherence to established corporate governance practices.

Negatives

• No specific negative aspects are identified in this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The granted restricted share units are scheduled to vest immediately prior to the next annual meeting of shareholders, converting into common shares.

Industry Context

This transaction represents a common form of non-employee director compensation in publicly traded companies, where equity grants like RSUs are used to incentivize directors and align their long-term interests with shareholder value creation. This practice is widespread across various industries, including the healthcare and pharmaceutical sectors where Bausch + Lomb operates.

Comparison to Industry Standards

• The grant of restricted share units (RSUs) as part of non-employee director compensation is a widely adopted practice across global public companies, including peers in the healthcare and vision care sectors.
• Companies like Johnson & Johnson (JNJ) and Alcon (ALC) also utilize equity-based compensation for their non-executive directors to foster alignment with shareholder interests.
• The vesting schedule, tied to the next annual meeting, is a common structure for annual director equity awards, ensuring continued engagement and oversight.

Corporate Governance

Related Party Transactions

• The grant of 20,338 restricted share units to Brett Icahn, a director of Bausch + Lomb Corporation, constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The equity grant to a director helps align the director's long-term interests with those of the shareholders, potentially leading to more shareholder-friendly decisions.

Next Steps

• The granted restricted share units are scheduled to vest immediately prior to the next annual meeting of shareholders.

Key Dates

Recommendation

Keywords

Bausch + Lomb, BLCO, Form 4, insider transaction, Brett Icahn, restricted share units, RSU, director compensation, equity grant, beneficial ownership